The CSHL Center for the Humanities and the History of Molecular Biology presents the 2023 Gardiner Lecture, to be given by Dr. Stelios Papadopoulos
Title: The Role of Capital Markets in the Evolution of Biotech
Date/time: Tuesday, December 19 at 4:00pm
Location: Bush Auditorium, Cold Spring Harbor Laboratory
RSVP: by Dec 15th to Tricia Loria at Loria@cshl.edu
Much has been said and many excellent books have been written about the rise of biotechnology and how scientists and entrepreneurs founded pathbreaking companies and developed important new drugs. None of that could have happened without billions of dollars of investment over the five decades of the industry’s life. That money came for the most part from Wall Street, and it is investors who make capital allocation decisions. What many industry observers may not appreciate is how the capital, and not scientists, established priorities and influenced the choice of scientific projects to be pursued.
About the lecturer :
Dr. Stelios Papadopoulos is the former Chairman of the Biogen Board of Directors.
Dr. Papadopoulos completed his graduate degrees at New York University: a MS in physics, PhD in biophysics, and MBA in finance. He was a faculty member in the Department of Cell Biology at New York University School of Medicine and maintained a position as Adjunct Associate Professor of Cell Biology as he transitioned into working in the biopharma industry as a company founder, advisor, and financier.
Dr. Papadopoulos was the biotechnology analyst at Donaldson, Lufkin & Jenrette before moving to Drexel Burnham Lambert as an analyst in the Equity Research Department for the biotechnology industry. He then joined PaineWebber, Inc., where he spent over ten years as an investment banker and held the position of Chairman of PaineWebber Development Corp. (a PaineWebber subsidiary focusing on biotechnology). He then joined Cowen & Co., LLC where he focused on the biotech and pharma sectors as an investment banker and eventually served as Vice Chairman. He has also been Chairman of the Board of Exelixis, Inc. and Regulus Therapeutics, Inc. He is a co-founder of Exelixis, Inc. as well as co-founder and former Chairman of Anadys Pharmaceuticals, Inc. and Cellzome, Inc. Papadopoulos was Chairman of the Board at Biogen from 2014 until he retired from the post in 2023.